drugset
Drugs / AAV9-Follistatin
last change Jun 2026 re-read 3 minutes ago

AAV9-Follistatin

Gene therapy (AAV / viral vector)

Developed for
muscular atrophy
Investigated by
Global Alliance for Regenerative Medicine · Unlimited Biotechnology LLC

Trials 1

today NCT07443826 · Ph 1/2
2027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07443826 Jun 2026 → Sep 2027 expected muscular atrophy Unlimited Biotechnology LLC Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AAV9-Follistatin ClinicalTrials.gov intervention name — accepted as the source's own label NCT07443826 ↗
Modality Gene therapy (AAV / viral vector) “AAV9 vector encoding human follistatin” NCT07443826 ↗
Route Intramuscular “administered via intramuscular injection into large skeletal muscles” NCT07443826 ↗